Pancreatic cancer trials in South Korea
54 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.
- No phaseTaking peopleChemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer
- Where
- Gyeonggi-do, Seoul
- Age
- 18 years to 85 years
- People
- 366 worldwide
- Run by
- IMGT Co., Ltd.
See details and how to joinNCT07325214 - Phase 1Taking peopleA Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- Where
- Haeundae, Seoul
- Age
- 18 years to 99 years
- People
- 600 worldwide
- Run by
- Erasca, Inc.
See details and how to joinNCT06983743 · EU 2026-525794-39-00 - Phase 1Taking peopleA Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Where
- Goyang-si Gyeonggi-do
- Age
- 18 years and over
- People
- 575 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00 - Phase 1Taking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- Seoul
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - Phase 2Taking peopleA Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Where
- Gangnam-Gu, Guro-gu, Hwasun-Eup, Jongno-gu, Seodaemun-gu, Seoul, Suwon
- Age
- 18 years and over
- People
- 200 worldwide
- Run by
- Jazz Pharmaceuticals
See details and how to joinNCT06695845 · EU 2024-516551-41-00 - Phase 2Taking peopleA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Jongno -Gu, Seoul
- Age
- 18 years and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00 - Phase 2Taking peopleA Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Where
- Seoul
- Age
- 18 years and over
- People
- 254 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07492680 - Phase 2Taking peopleBelzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Where
- Jongno-gu, Songpa-gu
- Age
- 12 years and over
- People
- 355 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00 - Phase 3Taking peopleA Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
- Where
- Cheongju-si, Incheon, Seongnam-si, Seoul, Suwon
- Age
- 18 years and over
- People
- 614 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07409272 · EU 2025-523684-38-00 - No phaseTaking peopleDevelopment and Utilization of an Integrated Clinical Genomic Database
- Where
- Seoul
- People
- 118,750
- Run by
- Samsung Medical Center
See details and how to joinNCT07911267 - Phase 2/3Taking peopleZanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Where
- Seoul
- Age
- 18 years and over
- People
- 440 worldwide
- Run by
- Exelixis
See details and how to joinNCT06943755 · EU 2025-521043-20-00 - Phase 3Taking peopleA Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- Where
- Goyang-si, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 588 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07522073 - Phase 1/2Taking peopleA Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- Where
- Seoul
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06428409 · EU 2023-508703-21-00 - Phase 1Taking peopleA Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
- Where
- Seoul
- Age
- 18 years and over
- People
- 404 worldwide
- Run by
- Astellas Pharma Inc
See details and how to joinNCT07094204 · EU 2025-522082-29-00 - Phase 1/2Taking peopleBOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
- Where
- Goyang, Seoul
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Bold Therapeutics, Inc.
See details and how to joinNCT04421820 · EU 2024-517500-11-00 - Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Daegu, Gyeonggi-do, Seongnam, Seoul
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 3Taking peopleStudy of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
- Where
- Busan, Seoul
- Age
- 18 years and over
- People
- 500 worldwide
- Run by
- Revolution Medicines, Inc.
See details and how to joinNCT07252232 · EU 2025-523495-23-00 - Phase 1/2Taking peopleA Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
- Where
- Seoul
- Age
- 18 years and over
- People
- 346 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06885034 - Phase 1Taking peopleStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Where
- Busan, Cheongju-si, Jinju, Seoul
- Age
- 18 years and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00 - Phase 2/3Taking peopleA Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- Where
- Busan, Daegu, Incheon, Seongnam, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 982 worldwide
- Run by
- Pfizer
See details and how to joinNCT06989437 · EU 2025-522093-36-00 - Phase 1/2Taking peopleStudy of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Where
- Seoul
- Age
- 18 years to 130 years
- People
- 695 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00 - Phase 3Taking peopleStudy of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Where
- Busan, Daegu, Seoul
- Age
- 18 years and over
- People
- 900 worldwide
- Run by
- Revolution Medicines, Inc.
See details and how to joinNCT07491445 · EU 2025-525088-34-00 - Phase 2Taking peopleAZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- Where
- Gyeonggi-do, Seoul
- Age
- 18 years and over
- People
- 226 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06219941 · EU 2023-508275-37-00 - Phase 1Taking peopleA Study of PHN-012 in Patients With Advanced Solid Tumors
- Where
- Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 165 worldwide
- Run by
- Pheon Therapeutics
See details and how to joinNCT07127874 - No phaseTaking peoplePancreatic Cancer Detection Consortium
- Where
- Seoul
- Age
- 18 years and over
- People
- 2,000 worldwide
- Run by
- City of Hope Medical Center
See details and how to joinNCT06388967